Affiliation:
1. From the Departments of Pathology, Urology, and Preventive Medicine, University of Southern California Keck School of Medicine; and University of Southern California/Kenneth Norris Comprehensive Cancer Center, Los Angeles, CA
Abstract
Purpose To determine the combined effects of p53, p21, and pRb alterations in predicting the progression of bladder transitional cell carcinoma. Patients and Methods p53, p21, and pRb expression was examined immunohistochemically on archival radical cystectomy samples from 164 patients with invasive or high-grade recurrent superficial transitional cell carcinoma (TCC; lymph node–negative, 117 patients; lymph node–positive, 47 patients). Median follow-up was 8.6 years. Based on percentage of nuclear reactivity, p53 was considered as wild-type (0% to 10%) or altered (> 10%); p21 was scored as wild-type (>10%) or altered (< 10%); and pRb status was considered wild-type (1% to 50%) or altered (0% or > 50%). Results As individual determinants, the p53, p21, and pRb status were independent predictors of time to recurrence (P < .001, P < .001, and P < .001, respectively), and overall survival (P < .001, P = .002, and P = .001, respectively). By examining these determinants in combination, patients were categorized as group I (no alteration in any determinant, 47 patients), group II (any one determinant altered, 51 patients), group III (any two determinants altered, 42 patients), and group IV (all three determinants altered, 24 patients). The 5-year recurrence rates in these groups were 23%, 32%, 57%, and 93%, respectively (log-rank P < .001), and the 5-year survival rates were 70%, 58%, 33%, and 8%, respectively (log-rank P < .001). After stratifying by stage, the number of altered proteins remained significantly associated with time to recurrence and overall survival. Conclusion This study suggests that alterations in p53, p21, and pRb act in cooperative or synergistic ways to promote bladder cancer progression. Examining these determinants in combination provides additional information above the use of a single determinant alone.
Publisher
American Society of Clinical Oncology (ASCO)
Reference34 articles.
1. Weinberg RA: How cancer arises. Sci Am 275:62,1996-70,
2. Cavanee WK, White RL: The genetic basis of cancer. Sci Am 272:72,1995-79,
3. A genetic model for colorectal tumorigenesis
4. Reznikoff CA, Belair CD, Yeager TR, et al: A molecular genetic model of human bladder cancer pathogenesis. Semin Oncol 23:571,1996-584,
5. Spruck CH III, Ohnesiet PF, Gonzalez-Zulueta M, et al: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54:784,1994-788,